Lanthio Pharma BV
https://www.lanthiopharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Lanthio Pharma BV
MorphoSys CEO Says Strategy To Build Proprietary Pipeline 'On Track'
MorphoSys CEO Simon Moroney tells Scrip that sales of Tremfya in the US and now Europe as a treatment for plaque psoriasis will help fund the German biotech's nascent proprietary pipeline.
Dezima Pharma Raises $18.6 Million For Next-Generation CETP Inhibitor
Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.
Aileron Overcoming Spirited Debate About Stapled Peptides
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.
With Dueling Papers Comes A Spirited Debate About Stapled Peptides
The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Drug Discovery Tools
- Molecular Diversity
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice